

C V (S H O R T) H E N N I N G B E C K - N I E L S E N

Professor Henning Beck-Nielsen, MD, DMSc
Odense University Hospital, Department of Endocrinology, Klovevraenget 6, 4th floor, 5000 Odense C, Denmark
28 June 1945

Henning Beck-Nielsen (HBN) is Professor of Endocrinology at the University of Southern Denmark and Consultant and Head of research at Odense University Hospital. He has been specialising in diabetes for the past 30 years. HBN has a high international reputation for his scientific work and has received a number of acknowledgements and awards.

Current positions

Professor of Endocrinology, Faculty of Health Sciences, University of Southern Denmark, Odense
Consultant, Department of Endocrinology, Odense University Hospital
Head of the Endocrine Research Unit (EFE), Odense University Hospital/University of Southern Denmark

Education and training (selected)

1985 Specialist of medical endocrinology (medical hormonal diseases)
1984 Specialist of internal medicine (medical diseases)
1980 Doctor of medical science: Insulin receptors in man. The monocyte as model for insulin receptor studies in man, defended at the Aarhus University, Denmark, 12 September 1980
1972 Diploma of doctor of medicine, Aarhus University, grade 10.3 (Danish 13-scale)

Doctoral and PhD assessments

Official opponent of 18 dissertations (1984-2012): 7 at the University of Copenhagen, Denmark, 6 at the University of Southern Denmark, Odense, Denmark, 3 at the University of Aarhus, Denmark, 1 at the University of Oslo, Norway, and 1 at the University of Helsinki, Finland. Assessor of 14 PhD theses (1993-2012).

Supervision of junior researchers

Terminated theses at EFE under my supervision: 7 doctoral dissertations, 30 PhD theses and 6 diploma theses. Currently supervisor for 8 PhD students.

Scientific publications

The scientific production comprises 423 original papers in total, including 25 book chapters. ISI Web of Science indicates 552 publications, including abstracts, cited more than 12,000 times. *h*-index 61. HBN has given approx. 370 lectures, of which approx. 255 as invited lecturer.

Selected publications

Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. *J Clin Invest* 1994 Nov;94(5):1714-21.

Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients: response to davidson and mikhael. *Diabetes Care* 2004 Jul;27(7):1847-8.

Ling C, Poulsen P, Carlsson E, Ridderstrale M, Almgren P, Wojtaszewski J, et al. Multiple environmental and genetic factors influence skeletal muscle PGC-1 α and PGC-1 β gene expression in twins. *J Clin Invest* 2004 Nov;114(10):1518-26.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet* 2009 Jun 20;373(9681):2125-35.

Vind BF, Pehmoller C, Treebak JT, Birk JB, Hey-Mogensen M, Beck-Nielsen H, et al. Impaired insulin-induced site-specific phosphorylation of TBC1 domain family, member 4 (TBC1D4) in skeletal muscle of type 2 diabetes patients is restored by endurance exercise-training. *Diabetologia* 2011 Jan;54(1):157-67.